Remove Genetic Engineering Remove Genetics Remove Marketing
article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. By building upon its core competency, Novo Nordisk Pharmatech will begin serving the emerging regenerative medicine and advanced therapy markets through best-in-class speciality enzymes.

Drugs 295
article thumbnail

Opinion: Where are the guidelines for the production of animals with intentional genomic alterations?

STAT News

Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint.  Salmon that reach market size in 18 months instead of 30.

Genome 98
article thumbnail

Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics) – ResearchAndMarkets.com

BioTech 365

Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics) – ResearchAndMarkets.com Genome Editing/Genome Engineering Market Research Report 2021: Technology (CRISPR, TALEN, ZFN, Antisense), Product & (..)

article thumbnail

Bone Therapeutics inks iPSC related research partnership

BioPharma Reporter

A new deal sees Bone Therapeutics gain access to iPSC derived, genetically engineered MSCs.

article thumbnail

First launch for Daiichi Sankyo’s oncolytic virus Delytact in Japan

pharmaphorum

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. million yen (around $12,500) per dose, according to a Pharma Japan report.